8-K: Maze Therapeutics Exchanges Shares for Warrants

Maze Therapeutics, Inc. has entered into an exchange agreement to swap a significant number of its common shares for pre-funded warrants with Frazier Life Sciences.

Summary

• Maze Therapeutics, Inc. (Maze) entered into an exchange agreement on October 15, 2026.
• The agreement was with Frazier Life Sciences Public Fund, L.P., Frazier Life Sciences X, L.P., Frazier Life Sciences XI, L.P., and Frazier Life Sciences XII, L.P. (collectively, the Exchanging Stockholder).
• Maze exchanged 2,776,007 shares of its common stock for pre-funded warrants to purchase an equivalent number of shares.
• The exercise price for these warrants is $0.001 per share.
• Following the exchange, Maze's outstanding common stock count as of October 16, 2026, is 53,931,889 shares.
• The warrants cannot be exercised if the holder would beneficially own more than 9.99% of the outstanding common stock, with certain exceptions.
• The issuance of these warrants is made without registration under the Securities Act of 1933, relying on the Section 3(a)(9) exemption.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative development, as it involves an exchange of existing shares for warrants, which can be perceived as a form of debt-like instrument or a precursor to future dilution, without a clear immediate benefit to the company's operational or financial standing.

Positives

• The exchange was conducted under an exemption from registration (Section 3(a)(9) of the Securities Act), potentially simplifying the process.
• The pre-funded warrants have a nominal exercise price of $0.001, which is favorable for the warrant holder upon exercise.

Negatives

• The company exchanged a substantial number of its own shares (2,776,007) for warrants, which could be interpreted as a move to manage short-term liquidity or obligations rather than a strategic growth initiative.
• The issuance of warrants, even pre-funded ones, represents potential future dilution of common stock.
• The restriction on beneficial ownership (9.99%) suggests a controlled relationship with the exchanging stockholder, but the underlying intent of the exchange is not explicitly stated as beneficial for the company's growth.

Risks

• Potential future dilution of common stock upon exercise of the pre-funded warrants.
• The terms of the exchange agreement and warrants are not fully detailed in the filing, with reference to exhibits for complete understanding.
• The reliance on Section 3(a)(9) exemption implies the transaction is with existing security holders, but the strategic rationale for this specific exchange is not elaborated.

Future Outlook

No specific forward-looking statements or guidance related to this transaction are provided in the filing. The primary forward-looking aspect is the potential exercise of the pre-funded warrants.

Management Comments

• No direct quotes or paraphrased statements from management regarding this specific transaction are included in the provided text.

Industry Context

StockSavvy.ai notes that exchanges of common stock for warrants, particularly with investment funds like Frazier Life Sciences, are not uncommon in the biotechnology and life sciences sector. These transactions can sometimes be used to restructure existing holdings or provide flexibility, but they also carry implications for future share structure and potential dilution.

Comparison to Industry Standards

• No direct comparison to industry standards or specific competitor actions is provided within this filing.
• The structure of exchanging shares for pre-funded warrants with a nominal exercise price is a known mechanism in venture capital and life sciences financing, often used to avoid immediate cash outlay for exercise and to provide a more defined path to potential future ownership.

Related Party Transactions

• The exchange agreement involves Frazier Life Sciences entities, which are identified as the 'Exchanging Stockholder'. This constitutes a transaction with a significant shareholder or investor group.

Stakeholder Impact

• Shareholders: Potential for future dilution of their ownership stake if warrants are exercised.
• Exchanging Stockholder: Gains pre-funded warrants, providing a right to acquire shares at a nominal price, with potential for future equity ownership and voting rights (subject to limitations).

Next Steps

• The Exchanging Stockholder may exercise the pre-funded warrants at any time after issuance, subject to beneficial ownership limitations.
• Maze Therapeutics, Inc. will be required to issue shares upon exercise of the warrants.

Key Dates

Keywords

Exchange Agreement, Pre-funded Warrants, Equity Securities, Securities Act Exemption, Frazier Life Sciences, Common Stock, Beneficial Ownership